Cell Growth & Differentiation, Vol 7, Issue 3 351-359, Copyright © 1996 by American Association of Cancer Research

ARTICLES

Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity

JA Dumont, AJ Bitonti, CD Wallace, RJ Baumann, EA Cashman and DE Cross-Doersen
Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215, USA.

We have isolated a variant of the MCF-7 human breast tumor that is characterized by a hormone-independent, yet hormone-responsive, phenotype. This tumor, designated MCF-WES, was derived from MCF-7 tumor cells implanted in the mammary fat pad of a nude mouse in the absence of estradiol supplementation. MCF-WES tumors remain responsive to estradiol; however, unlike the parental MCF-7 tumors, they are stimulated to grow by tamoxifen. Additionally, MCF-WES cells are resistant to the pure steroidal antiestrogen, ICI 182,780. To our knowledge, a tumor with this combination of properties has not yet been described. Nuclear estrogen receptor (ER) levels in MCF-WES cells were 10% of those for MCF-7 under steroid-depleted conditions. MCF-WES tumor ER levels were 32% of those in MCF-7 tumors. Similarly, in vivo expression of ER mRNA for MCF-WES was 20% of levels determined for MCF-7. Further characterization of MCF-WES cells showed that they have increased levels of AP-1 DNA-binding activity. The marked increase in AP-1 binding activity may act to bypass the hormone dependence that is a characteristic of MCF-7 cells. It is also probable that the increase in AP-1 binding activity is responsible for the finding that MCF-WES cells secrete greater quantities of metalloproteinase activity in comparison to parental MCF-7 cells, suggesting progression to a more invasive, malignant phenotype. More complete characterization of this new cell line will help elucidate hormone-independent breast cancer and possibly identify targets for therapy.

This article has been cited by other articles:

				L. Malorni, M. Giuliano, I. Migliaccio, T. Wang, C. J. Creighton, M. Lupien, X. Fu, S. G. Hilsenbeck, N. Healy, C. De Angelis, et al. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance Mol. Cancer Res., May 1, 2016; 14(5): 470 - 481. [Abstract] [Full Text] [PDF]

				M. Oyama, T. Nagashima, T. Suzuki, H. Kozuka-Hata, N. Yumoto, Y. Shiraishi, K. Ikeda, Y. Kuroki, N. Gotoh, T. Ishida, et al. Integrated Quantitative Analysis of the Phosphoproteome and Transcriptome in Tamoxifen-resistant Breast Cancer J. Biol. Chem., January 7, 2011; 286(1): 818 - 829. [Abstract] [Full Text] [PDF]

				Y. Zhang, H. Zhao, S. Asztalos, M. Chisamore, Y. Sitabkhan, and D. A. Tonetti Estradiol-Induced Regression in T47D:A18/PKC{alpha} Tumors Requires the Estrogen Receptor and Interaction with the Extracellular Matrix Mol. Cancer Res., April 1, 2009; 7(4): 498 - 510. [Abstract] [Full Text] [PDF]

				S. AUGUSTIN, M. BERARD, S. KELLAF, N. PEYRI, F. FAUVEL-LAFEVE, C. LEGRAND, L. HE, and M. CREPIN Matrix Metalloproteinases Are Involved in Both Type I (Apoptosis) and Type II (Autophagy) Cell Death Induced by Sodium Phenylacetate in MDA-MB-231 Breast Tumour Cells Anticancer Res, April 1, 2009; 29(4): 1335 - 1343. [Abstract] [Full Text] [PDF]

				S. Safe and K. Kim Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways J. Mol. Endocrinol., November 1, 2008; 41(5): 263 - 275. [Abstract] [Full Text] [PDF]

				R. B. Riggins, J. P-J. Lan, U. Klimach, A. Zwart, L. R. Cavalli, B. R. Haddad, L. Chen, T. Gong, J. Xuan, S. P. Ethier, et al. ERR{gamma} Mediates Tamoxifen Resistance in Novel Models of Invasive Lobular Breast Cancer Cancer Res., November 1, 2008; 68(21): 8908 - 8917. [Abstract] [Full Text] [PDF]

				A. Ring and M. Dowsett Mechanisms of tamoxifen resistance Endocr. Relat. Cancer, December 1, 2004; 11(4): 643 - 658. [Abstract] [Full Text] [PDF]

				Q.-B. She, N. Chen, A. M. Bode, R. A. Flavell, and Z. Dong Deficiency of c-Jun-NH2-terminal Kinase-1 in Mice Enhances Skin Tumor Development by 12-O-Tetradecanoylphorbol-13-Acetate Cancer Res., March 1, 2002; 62(5): 1343 - 1348. [Abstract] [Full Text] [PDF]

				M. J. Chisamore, Y. Ahmed, D. J. Bentrem, V. C. Jordan, and D. A. Tonetti Novel Antitumor Effect of Estradiol in Athymic Mice Injected with a T47D Breast Cancer Cell Line Overexpressing Protein Kinase C{alpha} Clin. Cancer Res., October 1, 2001; 7(10): 3156 - 3165. [Abstract] [Full Text] [PDF]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				L. Adam, R. Vadlamudi, M. Mandal, J. Chernoff, and R. Kumar Regulation of Microfilament Reorganization and Invasiveness of Breast Cancer Cells by Kinase Dead p21-activated Kinase-1 J. Biol. Chem., April 21, 2000; 275(16): 12041 - 12050. [Abstract] [Full Text] [PDF]

				A. H. Talukder, L. Adam, A. Raz, and R. Kumar Heregulin Regulation of Autocrine Motility Factor Expression in Human Tumor Cells Cancer Res., January 1, 2000; 60(2): 474 - 480. [Abstract] [Full Text]

				J. Y. Chung, C. Huang, X. Meng, Z. Dong, and C. S. Yang Inhibition of Activator Protein 1 Activity and Cell Growth by Purified Green Tea and Black Tea Polyphenols in H-ras-transformed Cells: Structure-Activity Relationship and Mechanisms Involved Cancer Res., September 1, 1999; 59(18): 4610 - 4617. [Abstract] [Full Text] [PDF]

				S. R. D. Johnston, B. Lu, G. K. Scott, P. J. Kushner, I. E. Smith, M. Dowsett, and C. C. Benz Increased Activator Protein-1 DNA Binding and c-Jun NH2-Terminal Kinase Activity in Human Breast Tumors with Acquired Tamoxifen Resistance Clin. Cancer Res., February 1, 1999; 5(2): 251 - 256. [Abstract] [Full Text] [PDF]

				P. Bhat-Nakshatri, T. R. Newton, R. Goulet Jr., and H. Nakshatri NF-{kappa}B activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1{alpha} PNAS, June 9, 1998; 95(12): 6971 - 6976. [Abstract] [Full Text] [PDF]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]